Share on StockTwits

Smith & Nephew plc (LON:SN)‘s stock had its “buy” rating reiterated by investment analysts at Deutsche Bank in a note issued to investors on Monday. They currently have a GBX 1,125 ($18.91) price target on the stock. Deutsche Bank’s target price suggests a potential upside of 5.53% from the company’s current price.

Shares of Smith & Nephew plc (LON:SN) traded up 1.04% during mid-day trading on Monday, hitting GBX 1077.11. The stock had a trading volume of 780,273 shares. Smith & Nephew plc has a one year low of GBX 720.00 and a one year high of GBX 1136.00. The stock’s 50-day moving average is GBX 943.1 and its 200-day moving average is GBX 900.5. The company’s market cap is £9.619 billion.

Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Friday. They now have a GBX 1,000 ($16.81) price target on the stock. Separately, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Smith & Nephew plc in a research note on Thursday. Finally, analysts at Credit Suisse reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note on Thursday. They now have a GBX 865 ($14.54) price target on the stock. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. Smith & Nephew plc has a consensus rating of “Hold” and a consensus target price of GBX 929.31 ($15.62).

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.